OMEICOS
Key Facts
| Invested since | 2013 |
| Based in | Berlin |
About the company
OMEICOS Therapeutics develops a novel, first-in-class, small molecule drug addressing a new Mode of Action for the treatment and prevention of atrial fibrillation.
Do you want to
know more about this company?
OMEICOS in the news
Zum Artikel
OMEICOS Therapeutics Raises EUR 6.2 Million in Series A to Advance Lead Candidate in Atrial Fibrillation
More startups from Life Sciences
Akribion Therapeutics is developing a unique, RNA-guided, nuclease-based technology for programmable cell depletion. Our G-dase® E nuclease has the ability to kill cells by shredding DNA and RNA, but only …
To the complete profileof Akribion Therapeutics
Synendos is developing first-in-class inhibitors that modulate a newly identified drug target in the body’s endocannabinoid system, enabling restoration of endogenous cannabinoid levels that are suppressed in certain pathological conditions. …
To the complete profileof Synendos Therapeuthics
Umlaut.bio GmbH develops small molecules that are intended to be used as first-in-class therapeutics against a variety of diseases. The focus is on the “umlauts” of the genetic code – …
To the complete profileof Umlaut.bio
Exit
Research, development and marketing of high-precision laser-based endoscopic and microscopic measuring systems for different application of minimal invasive surgery. Our products intend to make surgical interventions safer while optimizing costs.
To the complete profileof Scopis
PraxisEins is a state-supported practice network with the aim of solving the impending GP care vacuum. In order to avert the structural undersupply in large parts of the country, the …
To the complete profileof PraxisEins
Altavo is a Dresden based medical technology startup founded in February 2021. Based on non-invasive radar sensing and AI algorithms for speech recognition and synthesis, Altavo is developing prosthetics to …
To the complete profileof Altavo
Draupnir Bio is a spin out company, from Aarhus University and the Max-Planck Society and establishing itself at the forefront of protein degradation. Draupnir’s novel and proprietary platform technology is …
To the complete profileof Draupnir Bio
Exit
Provecs Medical develops novel products from its platform technology for cancer treatment by specific activation of the immune system. Exit since July 2015.
To the complete profileof Provecs Medical
SciRhom GmbH is a therapeutic antibody company developing first-in-class antibodies against iRhom2, a key modulator of several major pro-inflammatory signaling pathways, including TNF-alpha signaling. Based on a decade of cutting-edge …
To the complete profileof SciRhom
Lignopure GmbH is a spin-off of the TU Hamburg that enables the valorization of Lignin, a byproduct of ethanol biorefineries and the pulp and paper industry, via a proprietary technology. …
To the complete profileof Lignopure
ADVANOVA was founded in January 2012 by Dr. Frank Hemer, a doctor and computer scientist, and Bastian Bleisinger, a computer scientist. The company’s head office is in Erlangen at the …
To the complete profileof Advanova
The company was founded in 2022 and is headquartered at the STIMULATE research campus in Magdeburg’s “science-harbour”. The scientific company is a spin-off by scientists from the Otto-von-Guericke-University Magdeburg. The …
To the complete profileof RAYDIAX